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Abstract:  The emergence of  pandemic  H1N1 influenza  viruses  in  April 2009 and the 
continuous evolution of highly pathogenic H5N1 influenza viruses underscore the urgency 
of novel approaches to chemotherapy for human influenza infection. Anti-influenza drugs 
are currently limited to the neuraminidase inhibitors (oseltamivir and zanamivir) and to M2 
ion channel blockers (amantadine and rimantadine), although resistance to the latter class 
develops  rapidly.  Potential  targets  for  the  development  of  new  anti-influenza  agents 
include the viral polymerase (and endonuclease), the hemagglutinin, and the non-structural 
protein NS1. The limitations of monotherapy and the emergence of drug-resistant variants 
make  combination  chemotherapy  the  logical  therapeutic  option.  Here  we  review  the 
experimental data on combination chemotherapy with currently available agents and the 
development of new agents and therapy targets. 
Keywords:  combination  therapy;  antivirals;  influenza  virus;  neuraminidase  inhibitors; 
oseltamivir; amantadine; ribavirin 
 
1. Introduction  
Influenza continues to cause an unacceptable number of deaths and substantial economic losses 
worldwide. Although vaccination strategies are the mainstay of influenza control and prevention, the 
efficacy of this approach can be limited by the four-to-six-month minimum time required to produce a 
specific vaccine against a newly emergent virus, a poor match between the vaccine and the circulating 
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strain,  and  poor  immune  responses  among  elderly  patients  [1].  Influenza  virus  infection  can  be 
effectively treated with anti-influenza antiviral agents [2,3], as it was during the rapid emergence of 
the pandemic H1N1 influenza virus in 2009 when no vaccine was available. At present, two classes of 
antiviral drugs are approved for influenza therapy: M2 ion channel blockers (oral amantadine and its 
derivative rimantadine) and neuraminidase (NA) inhibitors (oral oseltamivir and inhaled zanamivir). 
These agents either prevent viral uncoating inside the cell (M2-blockers) or prevent the release of 
progeny virions from infected cells (NA inhibitors). The development of resistance is a major obstacle 
to the usefulness of both classes of anti-influenza agents, which could provide a growth advantage to 
variants carrying drug-resistance mutations, more likely under drug selective pressure. The emergence 
of  pathogenic,  transmissible,  amantadine-resistant  H1N1  and  H3N2  seasonal  influenza  variants, 
amantadine resistance in the pandemic H1N1 2009 influenza viruses, and a significant increase in 
amantadine resistance among some highly pathogenic H5N1 viruses, have limited the usefulness of 
M2 ion channel blockers [4-7]. The NA inhibitor resistance-associated mutations in influenza viruses 
are drug-specific and NA subtype-specific [8]. In experimental animal models, it was shown that the 
NA  inhibitor  resistant  variants  differed  in  fitness  and  transmissibility;  this  difference  may  be 
influenced by the location of NA mutation(s) [9-11]. These findings indicated that transmissible NA 
inhibitor  resistant  variants  may  emerge,  and  therefore  continuous  monitoring  for  NA  inhibitor 
resistance is necessary. Until 2007, influenza viruses resistant to the NA inhibitor oseltamivir were 
isolated at a low level. The incidence of oseltamivir resistance seen in clinical trial samples was 0.33% 
(4/1228) in adults/adolescents (≥13 years), 4.0% (17/421) in children (1 ≤ 12 years) and 1.26% overall 
[12]. However, during the 2007-2008 influenza season, oseltamivir-resistant variants with the H275Y 
NA amino acid substitution (N1 numbering) became widespread, first in the Northern Hemisphere 
[13,14] and then in the Southern Hemisphere [15]. Importantly, oseltamivir-resistant variants have 
rarely been reported among the novel pandemic H1N1 influenza viruses that emerged in April 2009 
[16], and oseltamivir is the treatment agent favored by clinicians [17,18].  
An attractive approach for countering drug resistance is combination chemotherapy with two or 
more  drugs  that  target  different  viral  proteins  or  host  factors  and  for  which  the  mechanisms  of 
resistance differ. Such combination therapy may reduce the likelihood that resistance to a single drug 
will emerge and reduces the effect of resistance that does emerge. Moreover, combination therapy may 
not only potentiate antiviral activity but may also enhance clinical outcomes by allowing reductions of 
the doses of individual drugs, thereby reducing dose-related drug toxicity and side effects. In addition, 
it can reduce the risk of respiratory complications (Figure 1).  
The  pharmacological  rationale  for  multiple-drug  combination  therapy  is  exemplified  by 
combination HIV treatment regimens that keep the plasma viral load below detectable levels, prevent 
the emergence of resistance, and allow successful management of HIV-infected patients [19,20]. This 
review  presents  the  experimental  and  available  clinical  data  on  combination  chemotherapy  for 
influenza  and  discusses  several  investigational  and  exploratory  agents  that  may  be  used  in 
combination. Viruses 2010, 2                                       
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Figure 1. Benefits of combination therapy for influenza. Combination therapy could target 
different viral proteins (A) that have different mechanisms of antiviral action (for example, 
NA inhibitor and M2 ion channel blocker), or (B) target virus and host factors that affect 
virus  replication  and  host  defense  mechanisms  (for  example,  NA  inhibitor  and 
immunomodulator).  This  diagram  represents  only  double  drug  combinations,  but  a 
multidrug approach could consist of three or more drugs in combination. Abbreviations: 
HA- hemagglutinin; NA - neuraminidase; M2 - matrix protein.  
 
 
2. Antiviral activity of drug combinations in cell culture 
The idea of using combination drug regimens to control influenza virus infection is not novel. For a 
number of years, investigators have studied the activity of combinations of various compounds against 
different subtypes of influenza virus in vitro and in vivo, seeking either synergistic or additive effects. 
Two or more drugs are combined to achieve critical experimental and potentially clinical end-points, 
producing interactions defined as “synergistic,” “additive,” or “antagonistic” when their combined 
effect  exceeds,  equals,  or  is  less  than  that  of  the  sum  of  the  effects  of  the  individual  drugs,  
respectively [21].  Viruses 2010, 2                                       
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The  results  of  various  studies  that  have  assessed  the  effects  of  the  double  and  triple  drug 
combinations on influenza virus infection in vitro are summarized in Table 1. Earlier studies showed 
that rimantadine  combined with the synthetic nucleoside ribavirin caused additive and,  at specific 
concentrations, synergistic inhibition of influenza A/FPV Weybridge (H7N7) virus infection in chick 
embryo  fibroblast  cell  cultures  [22].  Although  ribavirin  has  been  officially  approved  for  other 
conditions (hepatitis C and severe respiratory syncytial virus infection), it inhibits influenza A and B 
virus infection in vitro and in animal models [23-25]. Its metabolite ribavirin triphosphate inhibits the 
function of virus-coded RNA polymerases, which provides broad antiviral activity [23]. Rimantadine 
and  ribavirin  combinations  were  reported  to  reduce  human  influenza  A/Texas/1/77  (H3N2)  and 
A/USSR/90/77 (H1N1) virus yields in Madin-Darby canine kidney (MDCK) cells more than either 
agent alone [26]. Human interferon- and rimantadine or ribavirin additively or synergistically reduce 
the yield of clinical H3N2 or H1N1 influenza A isolates in primary rhesus monkey kidney cells [27]. 
Other  studies  have  tested  combination  regimens  that  included  experimental  compounds,  such  as 
polyoxometalate (PM)-523 [28], infusions of the natural antiviral agent Flos verbasci [29], and other 
plant preparations [30]. 
Discovery of the NA inhibitors was a significant milestone in influenza antiviral therapy [31-33] 
and introduced new options for combination chemotherapy. The NA inhibitor zanamivir combined 
with rimantadine, ribavirin, or 2’-deoxy-2’-fluoroguanosine showed additive effects against influenza 
A viruses in MDCK cells [34], and the NA inhibitor peramivir enhanced the reduction of virus yield in 
MDCK cells when combined with ribavirin [35]. Combinations that paired rimantadine with an NA 
inhibitor (zanamivir, oseltamivir carboxylate [active metabolite of oseltamivir], or peramivir) reduced 
extracellular H1N1 and H3N2 influenza virus yields in MDCK cells more efficiently than any of the 
drugs alone [36].  
A number of reports have described the activity of drug combinations against avian H5N1 influenza 
viruses in vitro. The yield of human A/Hong Kong/156/97 (H5N1) influenza virus in MDCK cells was 
reduced  significantly  more  than  by  monotherapy  (P<0.005)  when  the  cells  were  treated  with  the 
combination  of  amantadine  and  low-dose  (1 M)  oseltamivir  carboxylate  [37].  The  drug  pairs 
amantadine plus oseltamivir carboxylate and amantadine plus ribavirin acted synergistically over a 
range of doses against avian A/Duck/MN/1525/81 (H5N1) virus in MDCK cells [38], although this 
virus lacks the multibasic HA amino acid R-X-R/K-R motif required for high pathogenicity.  
Most studies have tested drug combinations against influenza viruses that were sensitive to both 
drugs. However, taking into consideration that all seasonal H3N2 and 2009 H1N1 influenza strains are 
resistant to amantadine [4,5,7], and the rapid emergence and spread of oseltamivir-resistant influenza 
viruses in 2007-2008 season [13-15], it is important to determine the efficacy of drug combinations 
against  drug-resistant  viruses. Smee  and  colleagues [38] found that the addition of amantadine to 
oseltamivir carboxylate did not improve activity against amantadine-resistant A/Duck/MN/1525/81 
(H5N1) virus in MDCK cells. The activity of a triple combination antiviral drug (TCAD) regimen 
(oseltamivir carboxylate, amantadine, and ribavirin) was tested against amantadine- and oseltamivir-
resistant seasonal influenza viruses in vitro [39]. Surprisingly, amantadine and oseltamivir carboxylate 
contributed to the TCAD regimen’s antiviral activity against amantadine- and oseltamivir-resistant 
viruses at concentrations that had shown no activity in single-agent testing and that were clinically 
achievable [39]. The interactions between M2, HA, and NA proteins on the surface of the influenza Viruses 2010, 2                                       
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particles are complex and not well understood. The authors suggested that as a result of protein-protein 
interactions between M2, HA and NA, the binding of a drug at one site may affect the confirmation 
and therefore affinity of the drug at another site [39].  
Table 1. Effect of the double and triple drug combinations on influenza virus infections in 
vitro. 
Drug 
combinations 
Influenza strain  
(subtype) 
Method of analysis  Drug interactions  Ref. 
Double combinations 
Rimantadine 
+ 
Ribavirin 
 
A/Chick/Germany/27  
(FPV Weybridge) (H7N7) 
a 
Virus yield inhibition (PFU)  Additive-
synergistic 
[22] 
A/USSR/77 (H1N1) 
A/Texas/77 (H3N2) 
Virus yield inhibition (PFU)  Additive-
synergistic 
[26] 
A/England/80 (H1N1) 
b 
A/Aichi/68 (H3N2) 
B/Lee/40 
Virus yield inhibition (PFU)  Subadditive- 
additive-synergistic 
[27] 
A/Virginia/87 (H1N1) 
A/Virginia/88 (H3N2) 
Virus yield inhibition (ELISA)  Additive 
 
[34] 
Amantadine 
+ 
Ribavirin 
 
A/USSR/90/77 (H1N1) 
A/Texas/1/77 (H3N2) 
A/New Jersey/76 (H1N1) 
Virus yield inhibition (PFU)   Enhanced 
inhibitory effect 
[26] 
A/Duck/MN/1525/81 (H5N1)  Virus yield inhibition (TCID50)  Synergistic 
c  [38] 
A/Duck/MN/1525/81 (H5N1) 
d  Virus yield inhibition (TCID50)  No added benefit 
c  [38] 
A/California/04/09 (H1N1) 
e 
A/California/05/09 (H1N1) 
e 
A/California/10/09 (H1N1) 
e 
Virus yield inhibition  
(NR staining) 
Additive 
c 
 
[39] 
Zanamivir 
+ 
Ribavirin 
A/Virginia/87 (H1N1) 
A/Virginia/88 (H3N2) 
Virus replication inhibition 
(ELISA) 
Additive 
 
[34] 
Zanamivir 
+ 
Rimantadine 
A/New Caledonia/20/99 (H1N1) 
A/Panama/2007/99 (H3N2) 
Virus (TCID50, MDCK) and 
cell-associated yield inhibition 
(ELISA) 
Additive- 
synergistic 
c 
[36] 
Oseltamivir 
carboxylate 
+ 
Amantadine 
 
A/Nanchang/1/99 (H1N1) 
A/Panama/2007/99 (H3N2) 
A/Hong Kong/156/97 (H5N1) 
Virus yield inhibition (PFU)  Enhanced 
inhibitory effect 
[37] 
A/California/04/09 (H1N1) 
e 
A/California/05/09 (H1N1) 
e 
A/California/10/09 (H1N1) 
e 
Virus yield inhibition  
(NR staining) 
Additive 
c 
 
[39] 
A/Duck/MN/1525/81 (H5N1)  Virus yield inhibition (TCID50)  Synergistic 
c  [38] 
A/Duck/MN/1525/81 (H5N1) 
d  Virus yield inhibition (TCID50,)  No added benefit 
c  [38] 
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Table 1. Cont. 
Drug 
combinations 
Influenza strain  
(subtype) 
Method of analysis  Drug interactions  Ref. 
Oseltamivir 
carboxylate 
+ 
Ribavirin 
A/California/04/09 (H1N1) 
e 
A/California/05/09 (H1N1) 
e 
A/California/10/09 (H1N1) 
e 
Virus yield inhibition  
(staining with NR) 
Additive 
c 
 
[39] 
Oseltamivir 
carboxylate 
+ 
Rimantadine 
A/New Caledonia/20/99 (H1N1) 
A/Panama/2007/99 (H3N2) 
Virus (TCID50) and  
cell-associated yield inhibition 
(ELISA) 
Additive- 
synergistic 
c  
[36] 
Peramivir 
+ 
Rimantadine 
A/New Caledonia/20/99 (H1N1) 
A/Panama/2007/99 (H3N2) 
Virus (TCID50) and cell-
associated yield inhibition 
(ELISA) 
Additive- 
synergistic 
c 
[36] 
Peramivir 
+ 
Ribavirin 
A/NWS/33 (H1N1)  Virus yield inhibition (TCID50)   Synergistic 
c 
 
[35] 
Triple combinations 
Oseltamivir 
carboxylate 
+ 
Amantadine 
+ 
Ribavirin 
A/New Caledonia/20/99 (H1N1) 
A/Sydney/05/97 (H3N2) 
A/Duck/MN/1525/81 (H5N1) 
Virus yield inhibition (TCID50), 
NR staining, RNA copies 
Highly synergistic 
c 
 
[40] 
A/California/04/09 (H1N1) 
e 
A/California/05/09 (H1N1) 
e 
A/California/10/09 (H1N1) 
e 
Virus yield inhibition  
(NR staining) 
Synergistic 
c 
 
[39] 
A/New Caledonia/20/99(H1N1)
d 
A/Wisconsin/67/05 (H3N2)
d 
A/Duck/MN/1525/81 (H5N1)
d 
Virus yield inhibition  
(NR staining) 
Additive 
c  [39] 
A/Mississippi/3/01 (H1N1) 
f 
A/Hawaii/21/07 (H1N1) 
f 
Virus yield nhibition  
(NR staining) 
Synergistic 
c 
 
[39] 
Note:  Drug  interactions  were  evaluated  based  on  inhibition  of  extracellular  (in  some  experiments  
cell-associated) virus yield or virus replication in Madin Darby canine kidney (MDCK) cells (unless otherwise indicated). 
Unless  indicated,  the  viruses  were  sensitive  to  all  drugs  used  in  the  study.  
Abbreviations:  Ref.  =  references;  PFU  =  plaque  forming  units;  TCID  =  tissue  culture  infectious  dose;  
ELISA = enzyme linked immunosorbent assay; NR = neutral red. 
a Studies were done in chick embryo fibroblasts cells.  
b  Studies  were  done  in  primary  rhesus  monkey  kidney  cells. 
c  Drug-drug  interactions  were  analyzed  by  the  
three-dimensional  model  of  Prichard  and  Shipman  [33]  using  the  MacSynergy
TM  II  software  program.  
d Amantadine-resistant influenza virus variant (shown in italic).
e Alternative subtype designation – (H1N1 pdm 2009).  
f Oseltamivir-resistant influenza virus variant (shown in italic). Viruses 2010, 2                                       
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The activity of a TCAD regimen (oseltamivir carboxylate, amantadine, and ribavirin) against H1N1 
2009  pandemic  (A/California/04/09,  A/California/05/09,  and  A/California/10/09)  and  three  other 
influenza  viruses  [(A/New  Caledonia/20/99  (H1N1),  A/Sydney/05/97  (H3N2)  and 
A/Duck/MN/1525/81 (H5N1)] was assessed on the basis of cytopathic effect inhibition in MDCK cells 
[39,40]. Importantly, this triple combination proved to be highly synergistic, and the synergy of the 
TCAD  regimen  was  significantly  greater  than  that  of  any  double  combination  tested  (P  <  0.05), 
including a combination comprising two NA inhibitors. This synergy was observed at concentrations 
achievable in human plasma at doses previously shown to be safe [39]; therefore, it may produce a 
markedly improved clinical outcome. Because combination treatment may inhibit the selection and 
outgrowth of drug-resistant viruses by reducing the number of replication cycles, it may also reduce 
the proportion of virus particles carrying resistance mutations. Ilyushina and colleagues [37] tested in 
vitro  the  hypothesis  that  combinations  of  amantadine  and  oseltamivir  carboxylate  can  prevent  or 
reduce  the  emergence  of  drug-resistant  variants.  It  was  shown  that  even  low  concentrations  of 
oseltamivir carboxylate prevented the emergence of amantadine-resistant variants of the H1N1, H3N2, 
and H5N1 subtypes grown in the presence of the two drugs in MDCK cells [37].  
An important initial step in  the evaluation of combination therapy is to determine whether the 
combined agents reduce influenza virus replication additively, synergistically, or antagonistically. A 
three-dimensional  approach  that  allows  a  complete  analysis  of  all  tested  drug  concentrations  and 
biological  effects  is  considered  the  most  suitable  model  for  analysis  of  drug  interactions  [41]. 
However, the available data on the synergistic interactions of different drugs are inconsistent to a 
degree. These differences may be attributed to the specific doses of each drug used in the studies; 
different influenza virus strains and passage history; different multiplicities of infection; different cell 
types, levels of confluence, and cell stocks; and different experimental designs. The endpoints used in 
studies also vary, these have included (1) inhibition of virus-induced cytopathic effects as determined 
by staining with neutral red, (2) inhibition of extracellular virus yields as shown by infectivity (plaque 
reduction assay and 50% tissue culture infectious dose [TCID50]) with and without drug pressure, (3) 
inhibition  of  cell-associated  virus  yields  in  MDCK  cells  as  shown  by  microneutralization  and 
subsequent enzyme-linked immunosorbent assay (ELISA), and (4) inhibition of RNA copy number. 
Therefore, a standard approach is needed to evaluate antiviral activity and drug interactions in in vitro 
systems. Furthermore, in vitro studies of multidrug regimens must be followed by animal experiments 
and  clinical  trials  to  define  dose  requirements  and  dose-response  relationships  between  antiviral 
agents.  
3. Antiviral activity of drug combinations in vivo 
A  number  of  animal  studies  have  demonstrated  the  benefits  of  combination  chemotherapy  for 
influenza  virus  infection  [35,38,42-45].  The  experimental  data  on  antiviral  activity  of  double  drug 
combinations against influenza A and B viruses in a lethal mouse model are summarized in Table 2.  Viruses 2010, 2                                       
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Table 2. Antiviral activity of double drug combinations against influenza A and B viruses 
in a lethal mouse model. 
Drug 
combinations 
Influenza strain (subtype), 
challenge dose/mouse 
Drug 
treatment 
Drug 
interactions 
Ref. 
Oseltamivir 
+ 
Amantadine 
A/Puerto Rico/8/34 (H1N1) 
a  24 h 
b  Enhanced protection  [45] 
A/Hong Kong/1/68 (H3N2) 
a  24 h   Enhanced protection  [45] 
A/Vietnam/1203/04 (H5N1), 10 MLD50  24 h  Greater protection than 
monotherapy 
[43] 
 
A/Vietnam/1203/04 (H5N1) 
c, 10 MLD50  24 h  No added benefit  [43] 
A/Duck/MN/1525/81 (H5N1), 
10
4 TCID50 
4 h  Greater protection than 
monotherapy 
d 
[38] 
A/Duck/MN/1525/81 (H5N1) 
c, 10
5 TCID50  4 h  No added benefit 
d  [38] 
Oseltamivir 
+ 
Rimantadine 
A/Quail/Hong Kong/G1/97 (H9N2) 
e,  
5 or 100 MLD50 
4 h  Greater protection than 
monotherapy 
[50] 
A/Aichi/2/68 (H3N2), 10 or 20 MLD50  4 h  Synergistic 
d  [42] 
Oseltamivir 
+ 
Ribavirin 
A/New Caledonia/20/99 (H1N1) 
e,  
10
6 TCID50 
24 h  No added benefit  [25] 
B/Sichuan/379/99 
e, 10
4 TCID50  24 h  Synergistic  [25] 
A/Duck/MN/1525/81 (H5N1), 
10
4 TCID50 
4 h  Greater protection than 
monotherapy 
d 
[38] 
A/Duck/MN/1525/81 (H5N1) 
e, 10
5 TCID50  4 h  No added benefit 
d  [38] 
A/Vietnam/1203/04 (H5N1), 5 MLD50  4 h, 
8 days 
Additive at some 
concentrations 
d 
[44] 
A/Turkey/15/06 ( H5N1), 5 MLD50  4 h, 
8 days 
Additive at some 
concentrations 
d 
[44] 
Amantadine 
+ 
Ribavirin 
A/Duck/MN/1525/81 (H5N1), 10
4 TCID50  4 h  Greater protection than 
monotherapy 
d 
[38] 
A/Duck/MN/1525/81 (H5N1) 
e, 10
5 TCID50  4 h  No added benefit 
d  [38] 
Peramivir 
+ 
Ribavirin 
A/NWS/33 (H1N1), 10
4 TCID50  4 h  Additive-synergistic 
d  [35] 
Oseltamivir 
+ 
T-705 
A/NWS/33 (H1N1), 10
4 TCID50  24 h  Strong synergy 
d  [60] 
A/Victoria/3/75 (H3N2), 10
4 TCID50  24 h  Strong synergy 
d  [60] 
A/Duck/MN/1525/81 (H5N1), 10
4 TCID50  2 h  Strong and minor synergy 
d  [60] 
Note: Drug interactions were evaluated on the basis of survival benefits provided by administration of drug combinations. 
Unless indicated, the viruses were sensitive to all drugs used in the study. Abbreviations: Ref. = references; MLD = mouse 
lethal dose; TCID = tissue culture infectious dose.
 a Infectious virus was administered to mice using a 1-2 µm diameter 
particle aerosol in a Middlebrook Airborne Infection Apparatus. 
b Unless indicated, the drugs were administered orally, 
twice daily for five days. Time indicates initiation of treatment before virus inoculation.
 c Amantadine-resistant influenza 
virus variant (shown in italic).
 d Drug-drug interactions were analyzed by the three-dimensional model of Prichard and 
Shipman [33] using the MacSynergy
TM II software program. 
e Mouse-adapted influenza virus variant. Viruses 2010, 2                                       
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The  mouse  model  is  the  only  animal  model  currently  used  for  evaluation  of  antiviral  drug 
combinations.  Analysis  of  drug  interactions  requires  a  sufficient  number  of  animals  per  group, 
informative parameters of evaluation (e.g., survival, weight loss, virus titers, and oxygen saturation) 
and a sufficient number of parameters for statistical evaluation. It is often difficult to determine drug 
interactions in animals because of small group sizes and the variability of effects at particular drug 
doses. Analysis can be complicated by variability in response rates at specific doses, in the parameter 
under evaluation, in the virus challenge dose, and in the timing of the initiation of antiviral treatment.  
The use of M2 blockers in combination with ribavirin or oseltamivir was associated with enhanced 
survival and was significantly more effective than either drug alone in a mouse model [46,47]. The 
therapeutic  synergism  of  aprotinin,  an  influenza  protease  inhibitor,  and  rimantadine  successfully 
protected mice from a lethal challenge with a mouse-adapted influenza virus [48]. The NA inhibitor 
peramivir was shown to interact additively and synergistically with ribavirin to reduce  A/NWS/33 
(H1N1) influenza infection with no enhancement of toxicity in mice [35]. Synergistic interaction was 
reported when rimantadine and oseltamivir were given to mice that had been intranasally inoculated 
with 10 or 20 50% mouse lethal doses (MLD50) of A/Aichi/2/68 (H3N2) virus when the compounds 
were administered simultaneously for five days, starting 4 h before inoculation [42]. 
Laboratory mouse-adapted influenza virus strains are customarily used in these studies, and they 
usually do not accurately represent the viruses currently circulating in nature. However, there have 
been attempts to study more recent influenza strains. Two new lethal infection models in mice were 
developed  using  mouse-adapted  influenza  A/New  Caledonia/20/99  (H1N1)  and  influenza 
B/Sichuan/379/99 viruses to study oral treatment with oseltamivir and ribavirin, both alone and in 
combination [25]. The activity  of oseltamivir-ribavirin combinations  against these viruses  differed 
from that reported for older, more established virus strains: oseltamivir was less effective and ribavirin 
was  more  active  against  A/New  Caledonia/20/99  (H1N1)  and  B/Sichuan/379/99  influenza  
viruses [25]. 
Human infection with highly pathogenic avian H5N1 influenza viruses  differs from infection with 
seasonal  human  H1N1  or  H3N2  viruses  mainly  in  that  the  H5N1  viruses  have  high  replication 
efficiency,  are  disseminated  beyond  the  respiratory  tract  (causing  multiorgan  failure),  and  induce 
hypercytokinemia  [49].  Although  the  mechanisms  of  these  multiple  pathogenic  effects  in  humans 
remain to be defined, preclinical animal studies provide an excellent prototype for optimizing antiviral 
therapy against highly pathogenic H5N1 viruses. A significant body of information about the efficacy 
of  drug  combinations  against  H5N1  influenza  viruses  in  vivo  is  available.  In  a  mouse  model, 
oseltamivir  combined  with  amantadine  or  rimantadine  was  more  effective  than  monotherapy  with 
oseltamivir in preventing the death of mice infected with H5N1 or H9N2 viruses [50]. Combinations of 
amantadine  and  oseltamivir  were  tested  against  recombinant  amantadine-sensitive  and  amantadine-
resistant  A/Vietnam/1203/04  (H5N1)  influenza  virus  [43].  In  mice  lethally  challenged  with 
A/Vietnam/1203/04 (H5N1) influenza virus that was sensitive to both oseltamivir and amantadine, 
combination therapy produced an additive benefit: survival was 30% with oseltamivir alone, 60% with 
amantadine  alone,  and  90%  with  combination  treatment  [43].  This  combination  also  significantly 
decreased viral titers in the lungs and prevented spread to the brain. However, combination therapy was 
no better than oseltamivir alone against the amantadine-resistant A/Vietnam/1203/04 (H5N1) influenza 
virus. A similar effect was reported when amantadine-oseltamivir combinations were tested against Viruses 2010, 2                                       
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amantadine-resistant A/Duck/MN/1525/81 (H5N1) virus in mice [38]. In contrast, oseltamivir-ribavirin 
treatment significantly reduced the mortality of mice inoculated with A/Duck/MN/1525/81 (H5N1) 
influenza virus [38]. Oseltamivir and ribavirin showed principally additive efficacy against both clade 1 
and clade 2 H5N1 influenza viruses. However, the efficacy of the drug combination against two H5N1 
viruses differed: higher doses were required to protect mice against A/Turkey/15/06 virus than against 
A/Vietnam/1203/04 virus [44]. Despite the efficacy of ribavirin in these studies, its use is limited by a 
relatively small therapeutic index, induction of hemolytic anemia at high doses, high toxicity, and 
potential  teratogenic  effects  [23].  It  is  still  unclear  whether  combination  therapy  can  produce 
sufficiently synergistic effects to allow a reduction of the dose of ribavirin to acceptable and safe 
levels.  These  observations  highlight  the  need  for  additional  antiviral  agents  that  can  be  used  in 
combination with oseltamivir for the management of H5N1 influenza virus infections.  
4. Clinical data  
Preclinical studies have demonstrated the benefits of combination therapy over monotherapy in 
inhibiting virus replication and reducing the risk of the emergence of resistant viruses. However, the 
clinical evaluation of combination therapy with currently available agents has received little attention. 
Controlled clinical therapy trials are impeded not only by the difficulty of organizing them but also by 
the limited number of antiviral drugs available for use in combinations and the high level of resistance 
to the adamantanes (amantadine and rimantadine) in circulating influenza strains. Several years ago, 
the National Institute of Allergy and Infectious Diseases (NIAID) Antiviral Study Group compared 
outcomes among hospitalized adults with influenza who received either nebulized zanamivir plus oral 
rimantadine or nebulized saline placebo plus oral rimantadine [51]. These studies were undertaken 
before  the  spread  of  amantadine  resistance  worldwide.  Patients  treated  with  zanamivir  plus 
rimantadine demonstrated a nonsignificant trend toward fewer days of virus shedding and were less 
likely to have a severe cough. Moreover, no resistant variants were found in the group receiving 
combination  therapy,  while  2  of  11  patients  in  the  rimantadine  monotherapy  group  had  resistant  
virus [51].  
To detect unanticipated interactions of the drugs used in combinations, the pharmacokinetics of 
amantadine (100 mg orally twice daily) and oseltamivir (75 mg orally twice daily) administered alone 
and in combination for five days was evaluated in a randomized, crossover study (n = 17) [52]. The 
pharmacokinetics  of  amantadine  was  not  affected  by  coadministration  of  oseltamivir.  Similarly, 
amantadine  did  not  affect  the  pharmacokinetics  of  oseltamivir  or  its  metabolite,  oseltamivir 
carboxylate. There was no evidence of an increase in the frequency or severity of adverse events when 
amantadine and oseltamivir were used in combination [52].  
The pharmacokinetics and tolerability of the oseltamivir-probenecid combination were evaluated in 
healthy volunteers [53,54]. The two tested regimens were (1) oseltamivir 150 mg once a day and 
probenecid 500 mg orally four times a day for four days [53] and (2) 75 mg of oral oseltamivir every 
48  h  and  500  mg  of  probenecid  four  times  daily  for  15  days  [54].  Subjects  who  received  both 
oseltamivir and probenecid had an oseltamivir carboxylate plasma concentration 2-2.5 times that of 
subjects who received oseltamivir alone. Probenecid inhibits renal tubular urate resorption and reduces Viruses 2010, 2                                       
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the excretion of several medications [55,56]. Therefore, the oseltamivir-probenecid combination must 
be used with caution in patients receiving renally excreted medications.  
Ongoing NIAID efforts  to  conduct clinical studies  of combination anti-influenza regimens will 
provide much-needed information on the prospects of this approach for the treatment of influenza. 
5. Investigational antiviral targets and agents 
There are currently few FDA-approved antiviral drug combinations, and more new antiviral drugs 
are urgently needed. Numerous attempts have been made to develop antiviral agents that target novel 
virus proteins or that act by novel mechanisms (Figure 2). Among these is the pyrazine molecule T-
705  (favipiravir,  6-fluoro-3-hydroxy-2-pyrazinecarboxamide).  The  mode  of  action  of  ribosylated, 
triphosphorylated  T-705  (T-705  RTP)  is  similar  to  that  of  ribavirin  triphosphate:  inhibition  of 
influenza virus RNA polymerase [57,58]. Unlike ribavirin 5 monophosphate, T-705 RMP only weakly 
inhibits  cellular  inosine  monophosphate  dehydrogenase  [58,59]  and  thus  is  less  cytotoxic.  These 
properties make T-705 a viable candidate influenza virus chemotherapy agent in humans. Phase II 
efficacy studies of T-705 were conducted in Japan during the 2007-2008 influenza season, and phase I 
studies were recently conducted in the United States. The benefits of using oseltamivir and T-705 in 
combination to treat H1N1, H3N2, and H5N1 influenza virus infection were recently demonstrated in 
a mouse model [60]. 
One  factor  in  the  unusual  severity  of  disease  caused  by  H5N1  influenza  viruses  is  cytokine 
dysregulation, including rapid accumulation of proinflammatory cytokines (“cytokine storm”) after 
infection [61,62]. Therefore, inhibitors of inflammation are a possible therapeutic approach. It was 
shown that mice treated with a triple combination of the NA inhibitor zanamivir and inhibitors of 
inflammation, such as celecoxib and mesalazine, had a significantly better survival rate, survival time, 
and level of inflammatory markers than mice treated with zanamivir alone [63]. Many studies have 
shown that oxidative stress is important in the pathogenesis of pulmonary damage during influenza 
virus infections. Antioxidant molecules are therefore potentially useful against viral infection. It was 
shown  that  antioxidant  molecule  N-acetylcysteine  (NAC)  in  combination  with  ribavirin  enhanced 
survival of mice against a lethal influenza virus infection [64]. Further studies have demonstrated that 
treatment of mice with  NAC combined with oseltamivir resulted in 100% survival [65], and thus 
suggest that antioxidant therapy increase survival by an improvement in host defense mechanisms, 
and/or by a direct antioxidant effect against oxidative stress associated with viral infection. In mice 
lethally  challenged  with  A/Aichi/2/68  (H3N2)  influenza  virus  the  combination  of  an 
immunostimulatory  bacterial  preparation  (cytoplasmic  membranes  of  Escherichia  coli  WF  stable 
protoplast type L-forms) with rimantadine resulted in synergistically increased protection, determined 
on the basis of virus lung titers, lung consolidation, mortality rates, protective indices, and survival 
times  [66].  However,  inclusion  of  novel  principals  for  the  treatment  of  human  influenza  virus 
infections,  including  H5N1  infection,  require  further  development  and  accumulation  of  strong 
experimental evidence.  
New formulations of conventional anti-influenza drugs and novel antiviral agents are currently at 
various stages of development. Parenteral administration of the NA inhibitors zanamivir (intravenous, 
IV) and peramivir (IV and intramuscular) are being evaluated in preclinical studies and clinical trials Viruses 2010, 2                                       
 
 
1521 
for the treatment of seasonal influenza A infection [67,68]. In Japan, peramivir has been licensed under 
the name Rapiacta® in 2010. Long-acting inhaled NA inhibitor (LANI) is a multimeric zanamivir 
compound (CS-8958) that persists longer in the lung and can be administered once weekly. These 
multimeric compounds have proven more potent than zanamivir and have provided the desired long-
acting  NA  inhibition  in  a  murine  model  of  influenza  infection,  including  infection  with  highly 
pathogenic H5N1 viruses [69,70]. Moreover, phase II clinical studies in Japan showed that a single 
inhaled dose of LANI was as effective as a standard five-day course of oseltamivir [71], and a double-
blind, randomized, controlled trial showed that  the LANI laninamivir octanoate was effective and 
well-tolerated in children with oseltamivir-resistant influenza A (H1N1) virus infection [72].  
Advances in understanding the mechanisms of influenza virus replication have revealed a number 
of potential drug targets. The influenza virus receptor inactivator DAS181 (Fludase), a sialidase fusion 
protein, has shown inhibitory activity against a large number of seasonal influenza strains and a highly 
pathogenic avian influenza H5N1 strain [73,74]. Thus far, DAS181 has been well tolerated with no 
serious adverse events in phase I trials, and phase II trials have begun [75].  
Other potential anti-influenza agents include Cyanovirin-N (CVN), a carbohydrate-binding protein 
that inhibits viral entry into cells by specifically binding to high-mannose oligosaccharides on the 
surface  glycoproteins  of  enveloped  viruses  [76];  small  interfering  RNAs  (siRNAs); 
immunomodulators; and immunotherapy with convalescent plasma and neutralizing antibodies. 
6. Conclusions 
The currently available influenza antivirals have a number of limitations; therefore, more effective 
antiviral  strategies  are  needed.  The  possibilities  include  parenteral  NA  inhibitors,  development  of 
novel antiviral drugs (polymerase and endonuclease inhibitors, sialidases, long-acting NA inhibitors, 
hemagglutinin  inhibitors,  and  non-structural  protein  NS1  inhibitors),  and  immunotherapy. 
Combination therapy with two or more drugs is a promising approach for control of seasonal influenza 
and of severe infection with highly pathogenic H5N1 influenza viruses. Drug combination studies in 
vitro  and  in  vivo  have  shown  the  potential  for  synergistic  or  additive  antiviral  activity  and  for 
inhibiting the development of resistance; these qualities must now be demonstrated in clinical trials. 
All of the available information supports the initiation of clinical trials on combination chemotherapy 
for influenza. The planning of such studies is ongoing, and consideration is being given to clinical and 
virologic evaluations with determination of influenza virus loads in the patient, the molecular and 
biological  characterization  of  viruses  for  resistance  and  fitness,  and  the  detailed  collection  of 
pharmacokinetic data to evaluate safety and toxicity. Future considerations for combination therapy 
are dual NA inhibitors, triple combinations, and inclusion of novel agents. The new strategies directed 
at unexplored targets, such as drugs that affect host antiviral responses, should be also developed.   
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Figure 2. Schematic representation of influenza virus replication cycle and sites of action 
of  antiviral  agents.  Note.  Influenza  A  virus  contains  eight  RNA  segments  of  negative 
polarity coding for at least 11 viral proteins. The surface proteins of influenza A virus 
consist of two glycoproteins, hemagglutinin (HA) and neuraminidase (NA), and the M2 
protein. The HA protein attaches the virus to sialic acid–containing receptors on the cell 
surface and initiates infection. A fusion protein inhibitor (DAS-181) targets the influenza 
virus receptor in the host respiratory tract and inhibits virus  attachment. Cyanovirin-N 
(CVN) binds to high-mannose oligosaccharides on HA and inhibits the entry of virus into 
cells.  For  most  influenza  A  viruses,  the  M2  ion  channel  blockers  (amantadine  and 
rimantadine) impede viral replication at an early stage of infection after penetration of the 
cell but prior to uncoating. M2 blockers inhibit the decrease in pH within the virion and 
thus block the release of viral RNA into the cytoplasm and prevent transportation of the 
viral genome to the nucleus. Inhibition of the viral polymerase, an essential component of 
viral RNA replication in the nucleus, can be blocked by the polymerase inhibitors ribavirin 
and T-705. Small interfering RNAs (siRNAs) that target different viral genes can inhibit 
viral replication. Several mechanisms of action have been proposed for the anti-influenza 
virus  activity  of  ribavirin.  One  is  the  inhibition  of  the  cellular  enzyme  inosine 
monophosphate  dehydrogenase,  resulting  in  a  decrease  in  the  intracellular  guanosine  
5′-triphosphate (GTP) that is required for nucleic acid synthesis. Ribavirin triphosphate 
also inhibits the function of virus-coded RNA polymerases which are necessary to initiate 
and elongate viral mRNAs. Late in infection, NA cleaves sialic acid–containing receptors 
and  facilitates  the  release  of  budding  virions.  NA  inhibitors  (zanamivir,  oseltamivir, 
peramivir, and LANI) block NA activity, preventing the release of virions from the cell.  
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